With links to Cochlear, the US-based med-tech company has global ambitions for its spinal cord stimulator technology.

Saluda Medical lists this Friday with the remit of tackling chronic pain with its Evoke spinal cord stimulation device.

The growth of the global bioelectric medicine market is propelled by various drivers including the increasing population of the geriatric group, rising burden of diseases necessitating the use of ...

The rising incidences of chronic pain, neurological disorders and mental health conditions continue to drive the demand for global neuromodulation devices. According to Grand View Research, the market ...

Spinal cord injury (SCI) rostral to the lumbar locomotor center disrupts communication between the brain and the spinal ...

O. Rose Broderick reports on the health policies and technologies that govern people with disabilities’ lives. Before coming to STAT, she worked at WNYC’s Radiolab and Scientific American, and her ...

The Global Spinal Implants And Surgery Devices Market Size projected to grow at a CAGR of 4.3% from 2026 to 2032, according ...

Saluda Medical Pty Ltd. announced a AU$231 million ($152.7 million) initial public offering on the Australian Securities ...

The pharmaceutical and medical device industries stand at an inflection point. After decades of reliance on traditional ...

Mordor Intelligence has published a new report on neuromodulation market offering a comprehensive analysis of trends, growth drivers, and future projections.

North suburban-based Abbott Laboratories announced a $21 billion deal Thursday morning to acquire Exact Sciences, the maker of Cologuard — its largest acquisition in a decade. The deal will allow ...